🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 04317A107
- IPO
- 7/19/2024 · $12.00/share
Business: Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. The Company's lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell killing properties of NK cells, when combined with mAbs for targeting, creates an opportunity to generate potentially transformative therapies.
Company Contact
- CEO
- Fred Aslan
- CFO
- Neha Krishnamohan
- Headquarters
- 5505 Morehouse Drive, Suite 100, San Diego, CA 92121
- Phone
- 858-267-4467
- Investor Relations
- %C2%A0ir@artivabio.com